QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A.

Qiagen (QGEN) announced that it has filed a complaint against bioMerieux for patent infringement. The complaint, filed in the Local Division of ...

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks ...

New QIAstat-Dx Gastrointestinal Panel 2 Mini B adds to QIAGEN’s growing U.S. menu for syndromic testing of gastrointestinal ...

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard ... The company serves more than 500,000 customers globally across Life Sciences and Molecular Diagnostics and employs over 5,700 people in over ...

The US Food and Drug Administration (FDA) has granted clearance to Qiagen’s QIAstat-Dx Gastrointestinal Panel 2 Mini B, expanding the company’s syndromic testing offerings in the US.

Explore Qiagen stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for QGEN. 18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year ...

(RTTNews) - QIAGEN N.V. (QGEN) announced that it has filed a complaint against bioMrieux S.A. for patent infringement, reinforcing its commitment to protecting the scientific advancements behind ...

About QIAGEN Certain statements in this press release ... commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of Qiagen NV (Symbol: QGEN) entered into oversold territory, hitting an RSI reading of 29.1 ...